35 research outputs found
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
BACKGROUND:
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes.
METHODS:
We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization.
RESULTS:
During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events.
CONCLUSIONS:
Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)
Recommended from our members
Microwave-Assisted Preparation of TiO2/Activated Carbon Composite Photocatalyst for Removal of Methanol in Humid Air Streams; Synthesis and characterization of hard magnetic composite photocatalyst—Barium ferrite/silica/titania; Flake Particle Synthesis from Ductile Metal Particles Using a Novel High-Speed Vibratory Mill; UV-Absorption-Based Measurements of Ozone and Mercury: An Investigation on Their Mutual Interferences; Aerosol Source Sampling in a Mid-Scale City, Gainesville, FL; Magnetically agitated photocatalytic reactor for photocatalytic oxidation of aqueous phase organic pollutants
A magnetically agitated photocatalytic reactor (MAPR) has been developed and assessed for oxidation of phenol. The MAPR uses a titanium dioxide composite photocatalyst with a ferromagnetic barium ferrite core. The catalyst motion was controlled with a dual-component magnetic field. First, a permanent magnet above the reactor provided a static magnetic field to counteract the force of gravity, hence increasing catalyst exposure to UV. Second, an alternating magnetic field generated by a solenoid was used to agitate the catalyst, thus increasing mass transfer between pollutants and byproducts to the catalyst. Optimal performance of the MAPR was achieved with the permanent magnet present and 1 A of alternating current to the solenoid between 20 and 80 Hz. Operating with a 60-Hz signal at 1 A with the permanent magnet present and 100 mg of catalyst, the system reduced an 11 mg/L phenol concentration by97% and decreased nonpurgeable dissolved organic carbon by 93% in 7 h using three 8-W 365-nm peak UV lamps